Hainan Dermavon Pharmaceutical Technology Co., Ltd.

Main objectives: 1. To quantitatively analyze the total radioactivity in the excrement of healthy male participants after oral administration of [14C] CMS-D001, and to obtain the human radioactivity recovery rate and main excretion pathway; 2. To investigate the partition ratio of total radioactivity in whole blood and plasma after oral administration of [14C] CMS-D001 in healthy male participants, and the pharmacokinetic characteristics of total radioactivity in whole blood (if applicable) and plasma; 3. To obtain the radiometabolite profiles of plasma, urine, and feces after oral administration of [14C] CMS-D001 in healthy male participants, identify the major metabolites, and determine the main biotransformation pathways. Secondary objectives: 1. To quantitatively analyze the plasma concentrations of CMS-D001, metabolite M414-2, and other major metabolites (if applicable) using a validated LC-MS/MS method, and to obtain the pharmacokinetic parameters of CMS-D001, M414-2, and other major metabolites (if applicable) in plasma; 2. To observe the safety of a single oral administration of [14C] CMS-D001 to healthy adult male participants in China.